Armata Pharmaceuticals Inc (ARMP)
2.25
+0.15
(+7.14%)
USD |
NYAM |
Nov 22, 16:00
2.25
0.00 (0.00%)
After-Hours: 20:00
Armata Pharmaceuticals Cash from Financing (Quarterly): -0.061M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.061M |
| June 30, 2024 | 0.088M |
| March 31, 2024 | 34.93M |
| December 31, 2023 | -0.043M |
| September 30, 2023 | 24.80M |
| June 30, 2023 | -0.368M |
| March 31, 2023 | 29.59M |
| December 31, 2022 | -0.50M |
| September 30, 2022 | 0.031M |
| June 30, 2022 | -0.146M |
| March 31, 2022 | 44.63M |
| December 31, 2021 | 7.038M |
| September 30, 2021 | 0.086M |
| June 30, 2021 | -0.185M |
| March 31, 2021 | 18.58M |
| December 31, 2020 | 0.432M |
| September 30, 2020 | 0.06M |
| June 30, 2020 | 0.306M |
| March 31, 2020 | 22.41M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 9.975M |
| March 31, 2019 | -1.00M |
| December 31, 2018 | 12.45M |
| Date | Value |
|---|---|
| September 30, 2018 | -6.406M |
| June 30, 2018 | -0.204M |
| March 31, 2018 | 6.61M |
| December 31, 2017 | -0.206M |
| September 30, 2017 | -0.611M |
| June 30, 2017 | 9.693M |
| March 31, 2017 | -0.205M |
| December 31, 2016 | 3.255M |
| September 30, 2016 | -0.017M |
| June 30, 2016 | 3.988M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | -0.001M |
| June 30, 2015 | 0.397M |
| March 31, 2015 | 12.38M |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 16.91M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 7.998M |
| March 31, 2013 | 0.976M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.50M
Minimum
Dec 2022
44.63M
Maximum
Mar 2022
9.084M
Average
0.087M
Median
Cash from Financing (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 0.137M |
| Perspective Therapeutics Inc | 0.628M |
| Protalix BioTherapeutics Inc | -20.42M |
| Electromed Inc | -4.467M |
| Xtant Medical Holdings Inc | 5.314M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.863M |
| Cash from Investing (Quarterly) | -0.34M |
| Free Cash Flow | -42.09M |
| Free Cash Flow Per Share (Quarterly) | -0.2544 |
| Free Cash Flow Yield | -44.90% |